{"id":59458,"date":"2022-12-08T21:10:11","date_gmt":"2022-12-08T21:10:11","guid":{"rendered":"https:\/\/elpais.com\/ciencia\/2022-12-08\/el-medicamento-mas-caro-del-mundo-un-nuevo-farmaco-para-terapia-genica-contra-la-hemofilia.html"},"modified":"2022-12-08T21:10:11","modified_gmt":"2022-12-08T21:10:11","slug":"el-medicamento-mas-caro-del-mundo-un-nuevo-farmaco-para-terapia-genica-contra-la-hemofilia","status":"publish","type":"post","link":"https:\/\/forocilac.org\/en\/el-medicamento-mas-caro-del-mundo-un-nuevo-farmaco-para-terapia-genica-contra-la-hemofilia\/","title":{"rendered":"The most expensive drug in the world: a new drug for gene therapy against hemophilia"},"content":{"rendered":"<p>Un medicamento innovador y eficaz, pero a un precio estratosf\u00e9rico. La inversi\u00f3n de las compa\u00f1\u00edas biotecnol\u00f3gicas en nuevas <a href=\"https:\/\/elpais.com\/sociedad\/2022-10-10\/el-avance-de-las-terapias-genicas-aumenta-la-presion-de-la-industria-farmaceutica-sobre-las-pruebas-del-talon.html\">terapias g\u00e9nicas<\/a> est\u00e1 permitiendo desarrollar f\u00e1rmacos para enfermedades que carec\u00edan de un tratamiento adecuado. Sin embargo, al repercutir en el precio los costes asumidos, convierten los nuevos compuestos en accesibles solo para unos pocos. El Hemgenix, una terapia g\u00e9nica contra la hemofilia <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treat-adults-hemophilia-b\" >reci\u00e9n aprobada por Estados Unidos<\/a>, se acaba de convertir en el medicamento m\u00e1s caro de la historia: 3,5 millones de d\u00f3lares (unos 3,3 millones de euros). Ser\u00e1 comercializada por CSL Behring.<\/p>\n<p><a href=\"https:\/\/elpais.com\/ciencia\/2022-12-08\/el-medicamento-mas-caro-del-mundo-un-nuevo-farmaco-para-terapia-genica-contra-la-hemofilia.html\" >Keep reading<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Treatment with Hemgenix, recently approved by the United States, costs 3.5 million dollars<\/p>","protected":false},"author":1650,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[123],"tags":[],"class_list":{"0":"post-59458","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-portal"},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/users\/1650"}],"replies":[{"embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/comments?post=59458"}],"version-history":[{"count":1,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59458\/revisions"}],"predecessor-version":[{"id":59459,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/posts\/59458\/revisions\/59459"}],"wp:attachment":[{"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/media?parent=59458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/categories?post=59458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forocilac.org\/en\/wp-json\/wp\/v2\/tags?post=59458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}